OI Therapy Raised BMD, Not Fracture Benefit
Teriparatide followed by zoledronic acid increased bone mineral density but did not reduce fracture risk compared with standard care in adults with osteogenesis imperfecta.
By
Andrea Surnit
June 5, 2026
Clinical Scorecard: OI Therapy Raised BMD, Not Fracture Benefit
At a Glance
Category Detail
Condition Key Mechanisms Target Population Care Setting
Key Highlights
No statistically significant reduction in fractures with teriparatide and zoledronic acid compared to standard care Significant improvement in bone mineral density in the intervention group High adherence rates to treatment in the intervention group (98.3%) Most patients had type I osteogenesis imperfecta Patient-reported outcomes favored the intervention group Guideline-Based Recommendations
Diagnosis
Management
Teriparatide followed by zoledronic acid for bone density improvement Standard care with discretion for other osteoporosis therapies Monitoring & Follow-up
Risks
Patient & Prescribing Data
350 adult patients with osteogenesis imperfecta
Teriparatide and zoledronic acid improved bone mineral density but did not reduce fracture incidence
Clinical Best Practices
Consider patient adherence when prescribing treatment Evaluate both bone density and fracture risk in management plans Related Resources & Content
